Introduction
============

Glaucoma, a chronic optic neuropathy, is characterized by a progressive loss of the retinal nerve fiber layer and visual field defects, related or not related to an increase of intraocular pressure (IOP) and, at present, is the third cause of irreversible blindness worldwide, with cataracts being the major cause.[@b1-opth-4-261]

In Spain, the prevalence of glaucoma in the population over 40 years is 1.5%, and increases in individuals over 60 years of age.[@b2-opth-4-261] Primary open angle glaucoma, known also as simple chronic glaucoma, is the most frequent type, accounting for up to 60% of glaucoma cases.

IOP, past family history, age, race, male gender, cup-disk ratio, a high standard deviation (SD) on Humphrey's visual field pattern, cardiovascular disease, and a thin Clinical Ophthalmology 2010:4 central cornea thickness are the primary risk factors for glaucoma (Ocular Hypertension Treatment Study). IOP is the only known risk factor which can be modified to halt disease progression, and all antiglaucomatous treatments are targeted to IOP.

In spite of the American Ophthalmology Academy recommendation to start with medical therapy, laser trabeculoplasty, or filtration surgery for glaucoma, most patients receive initial treatment with a topical hypotensive drug.[@b3-opth-4-261] If the prescribed hypotensive drug effectively reduces IOP, it might be assumed that the patient would indefinitely continue using this ocular hypotensive drug with the aim of obtaining clinical improvement.[@b4-opth-4-261] Various studies have demonstrated that reduced IOP decreases the risk of loss of visual field[@b5-opth-4-261] and slows the process of ocular hypertension (OHT) progression to glaucoma.[@b6-opth-4-261] Even so, many patients withdraw from topical hypotensive treatment of their own accord.[@b7-opth-4-261]--[@b14-opth-4-261]

Marketed topical prostaglandins, including latanoprost, approved by the European Medicines Agency (EMEA) in 1997, and bimatoprost and travoprost, approved in 2002 and 2001, respectively, effectively reduce IOP levels by increasing aqueous fluid drainage through the uveal-scleral route.

The last version of the European Ophthalmology Society guidelines, published in 2008, states that the objectives of glaucoma treatment are to assure effective IOP management from the outset to prevent development of glaucomatous damage and to concentrate on treatment efficacy, tolerability, and compliance. Collection of data on clinical effectiveness, reflecting the clinical results of drugs used common medical practice conditions, has become increasingly important.

One of the most important contributors to good results in clinical practice is the continuous taking of the prescribed drug by the patient for the time period considered necessary. Thus, it is important to identify the likely duration of persistence (period of time for which the patient takes the prescribed drug) with antiglaucomatous medication. If the period of time of continuous medication is short, the therapeutic benefit will be minor, and lower than the benefit that might have been achieved if the patient had taken the medication for a longer time. This will cause a need for a second- line therapy prescription, thus increasing consumption of potentially unnecessary health care resources.[@b15-opth-4-261]

Even though a number of factors may affect patient persistence with treatment, one of the most important ones is local tolerability. When tolerability is poor, patients are very likely to discontinue their medication or put pressure on the ophthalmologist to change their treatment. Another important issue is clinical effectiveness of therapy; if IOP levels continue to be high, the ophthalmologist will either opt for a change in medication or will add a second drug to reduce IOP further.[@b16-opth-4-261]

The objective of this study was to evaluate the extent of patient persistence with the drugs most commonly used as monotherapy for glaucoma in Spain (latanoprost, bimatoprost, travoprost, and timolol).

Materials and methods
=====================

An observational, retrospective study of glaucomatous patients was conducted in the ophthalmology departments of the Hospital de Torrevieja (Alicante), Centro de Oftalmología Barraquer (Barcelona), Fundación Hospital Alcorcón (Madrid), and Instituto Universitario de Oftalmobiología Aplicada (Valladolid).

The Ethics Committee for Clinical Research from the Fundación Hospital Alcorcón, Madrid, approved the protocol in December 2006. Due to the observational and retrospective nature of the study, for which data were obtained from review of medical charts, with no intervention or deliberate modification of biologic, physiologic, psychologic, or social variables, patient informed consent was not required.

Using the hospital databases, clinical charts for glaucomatous patients treated with commonly used monotherapy (timolol 0.5% twice daily, latanoprost 0.005%, bimatoprost 0.03%, or travoprost 0.004% once daily in the evening) were reviewed.

Inclusion criteria for the study were age over 18 years of age, a diagnosis of glaucoma or OHT, monotherapy with any of the study drugs between July 2003 and June 2004, and sufficient information in medical charts to monitor follow- up for at least 24 months after initiation of monotherapy. Patients may or may not have received antiglaucomatous treatment before the date of study initiation. Patients who had received concomitant antiglaucomatous treatment during the study period or whose medical charts did not contain reliable data for at least 24 months after monotherapy initiation were excluded.

Details of age, gender, time from diagnosis of glaucoma, last recorded IOP, associated comorbidities, previous glaucoma treatments, and antiglaucomatous monotherapy were collected from medical charts.

Every selected patient had been followed up at three, six, nine, 12, and 24 months, so we were able to identify dates and reasons for treatment discontinuation. Thus, any treatment changes during the 24-month follow-up period were able to be collected.

A persistent patient was defined as one who had taken the prescribed drug as monotherapy continuously during the 24-month study period. For patients who did not persist with antiglaucomatous treatment for 24 months, the days to treatment discontinuation or to a medication change/referral for surgery by the ophthalmologist was recorded. A medication change was defined as any change in monotherapeutic agent used or addition of another ocular hypotensive agent. For patients who discontinued treatment at any time during the study, reasons for discontinuation (intolerance, adverse effects, poor compliance, patient request, or lack of efficacy), as well as any changes in the therapeutic approach of the attending ophthalmologist (treatment change, addition of a new therapy, or referral for surgery) were recorded.

Ophthalmology medical charts from July 2003 to June 2004 were reviewed over a period of six months (from March to September 2007). A descriptive analysis of patient sociodemographic and clinical characteristics was conducted, which enabled a comparison of the extent of patient persistence and clinical variables between patients who initiated monotherapy with a prostaglandin or with a topical β-blocker (timolol). The distribution of each variable was analyzed in order to define possible recoding for both categoric and continuous variables. Variable recoding was based on three criteria, ie, to define clinically significant categories, to reduce as far as possible the number of categories, and to obtain the maximum homogeneity in the number of cases in each category.

To assess patient persistence with the study drug, a Kaplan--Meier survival analysis was done to estimate the persistence curves for patients treated with the different study medications over 24 months. To identify the statistical significance of patient persistence with the different study drugs, Log-Range, Tarone--Ware, and Breslow contrast tests were used. Finally, a Cox regression model was used to identify the predictive effect of variables on the degree of patient persistence, with time to discontinuation as a dependent variable, and age, gender, concomitant drugs, associated comorbidities, IOPs, time from diagnosis of glaucoma, previous glaucoma treatments, and antiglaucomatous monotherapy (latanoprost reference group) as independent variables. For the statistical analysis, the SPSS statistical program was used (version 14.0; SPSS Inc., Chicago, IL).

Results
=======

Of 191 patients who fulfilled our inclusion criteria, 87 had been initiated on treatment with latanoprost, 35 with bimatoprost, 26 with travoprost, and 43 with timolol. Demographic and clinical characteristics of these patients are summarized on [Table 1](#t1-opth-4-261){ref-type="table"}.

Approximately 60% of patients were female, and a statistically significant difference in gender ratio was found among the different treatment groups (*P =* 0.002). Mean patient age was 66.4 years (SD 14.0); the bimatoprost group showed the highest mean age, but age differences between groups were not statistically significant. Overall mean IOP was 16.9 mmHg (SD 2.9); no statistically significant differences by treatment were observed, although it should be noted that IOPs recorded in patients' medical charts were not always recorded on a date close to the initiation of follow- up. The mean time elapsed from the date patients had become aware of the diagnosis of glaucoma was 3.7 years (SD 3.6).

Forty-four percent of patients had received previous treatment for glaucoma. However, this percentage varied between treatments, the bimatoprost group having the highest percentage (74.3%), followed by latanoprost (46%). Timolol was the drug most frequently prescribed as an initial treatment after diagnosis, followed by brimonidine and carteolol. No significant differences were observed among treatment groups for comorbidities.

Numbers and rates of patient persistence throughout the study with the various prescribed drugs are shown in [Table 2](#t2-opth-4-261){ref-type="table"}. Only 36.1% of patients discontinued their treatment. When comparing persistence with the different study drugs, six possible combinations were analyzed. Latanoprost was statistical significant versus bimatoprost and timolol (*P =* 0.0001 and *P =* 0.01, respectively); but did not achieve statistical significance versus travoprost (*P =* 0.058), with a difference in persistence of 16.2%. Bimatoprost was found to be inferior versus travoprost and timolol (*P =* 0.003 and *P =* 0.001, respectively); travoprost and timolol did not show statistical significant (*P =* 0.8). Percentages and statistical significance of the differences in persistence with the study drugs are shown on [Table 3](#t3-opth-4-261){ref-type="table"}.

[Figure 1](#f1-opth-4-261){ref-type="fig"} shows a Kaplan--Meier survival plot where patient persistence is assessed over the 24 months. [Table 4](#t4-opth-4-261){ref-type="table"} shows percentages for treatment discontinuation. Differences were found between the four treatment groups for intolerance and/or adverse effects as well as for lack of efficacy variables (*P \<* 0.001). Fewer latanoprost-treated patients reported intolerance and/or adverse effects and fewer travoprost-treated patients reported lack of efficacy. The bimatoprost group showed higher rates of lack of efficacy compared with latanoprost, travoprost, and timolol.

For all possible variables with a predictive and/or modifying effect on patient persistence, only the choice of antiglaucomatous drug used in monotherapy and patient age were statistically significant. The risk of treatment discontinuation during the follow-up period was six-fold with bimatoprost versus latanoprost (*P \<* 0.0001) and 2.4-fold for timolol versus latanoprost (*P =* 0.01). An increased risk of 3.2% per year was observed with patient age (*P =* 0.001). Other variables analyzed were not related to duration of persistence.

Discussion
==========

This study indicated greater patient persistence with latanoprost than with other prostaglandins or the β-blocker timolol in routine clinical practice.

This is the first research done in Spain on patient persistence with antiglaucomatous treatment, and the obtained results are similar to those of studies conducted in other countries,[@b12-opth-4-261],[@b17-opth-4-261]--[@b20-opth-4-261] indicating greater patient persistence with latanoprost as a topical hypotensive therapy for glaucoma, which might be due to three factors. First, latanoprost has been shown to be more effective in IOP reduction than other therapies;[@b21-opth-4-261]--[@b24-opth-4-261] second, unlike timolol, latanoprost has a more convenient once-daily dosing schedule; and third, it has a lower rate of adverse effects, in particular for hyperemia, when compared with the other topical hypotensive drugs. Reported incidence rates for hyperemia in the clinical trials are 5%--10% for latanoprost,[@b25-opth-4-261] 15%--45% for bimatoprost,[@b26-opth-4-261] and 35%--50% for travoprost.[@b21-opth-4-261]

In a study conducted by Tingey et al, age, life expectancy, associated comorbidities, and satisfaction with treatment were the factors found to influence persistence with treatment and IOP control.[@b18-opth-4-261] The results of preliminary research have suggested that treatment with latanoprost is associated with greater persistence than with bimatoprost or travoprost,[@b10-opth-4-261],[@b12-opth-4-261],[@b13-opth-4-261],[@b17-opth-4-261],[@b22-opth-4-261]--[@b26-opth-4-261] and this is possibly due to its better tolerability.[@b10-opth-4-261]

In three independent, retrospective studies of US cohorts, each including over 1000 patients, and with follow-up periods between 18 and 30 months, patients who initially received latanoprost as a single agent continued treatment for significantly longer than patients treated with β-blockers, carbonic anhydrase inhibitors, or brimonidine.[@b8-opth-4-261]--[@b10-opth-4-261]

Recent clinical trials have documented that a low IOP in glaucomatous patients contributes to visual field preservation. [@b5-opth-4-261],[@b27-opth-4-261] Thus, low persistence with the ocular hypotensive drug will limit the clinician's ability to prevent visual loss related to glaucoma. Use of prostaglandin analogs, including latanoprost, bimatoprost, travoprost, and unoprostone, is related to higher persistence compared with other marketed hypotensive agents.[@b4-opth-4-261],[@b5-opth-4-261]

The concept of persistence with treatment allows better assessment of the effectiveness of a treatment, reflecting its use in daily practice and identifying any possible change (eg, treatment failure), regardless of the underlying cause.

The introduction of prostaglandins resulted in a simplified more convenient dosing schedule, enabling more effective IOP reduction. Furthermore, it resulted in surgery becoming a second-line treatment for glaucoma, to be used only when IOP levels cannot be controlled by these potent drugs.[@b28-opth-4-261] We now need to identify drugs for glaucoma with as few side effects as possible to ensure continuity of treatment.

In our study, 81.6% of latanoprost-treated patients had continued treatment at the end of the second year, while only 22.9% of bimatoprost-treated patients persisted. Patient persistence with travoprost and timolol was approximately 60%. These results are in agreement with those published by Diestelhorst et al[@b14-opth-4-261] who, in an observational and retrospective review conducted in 13 European centers, observed that patients who received initial treatment for primary open angle glaucoma or OHT with latanoprost as monotherapy continued taking their treatment for a time period twice that of those patients who had received a β-blocker, underwent fewer changes of therapy, and achieved a greater mean IOP reduction. All these differences were statistically significant (*P \<* 0.0001).

Discontinuation rates differed among the treatments. Fewer latanoprost-treated patients reported an ocular adverse event compared with those receiving bimatoprost, travoprost or timolol (*P \<* 0.001). These results are consistent with those published by Parrish et al where latanoprost also showed greater ocular tolerability.[@b29-opth-4-261] A possible factor influencing the poor efficacy of bimatoprost may be the patient having received previous treatment, which might create a negative comparison for the patient.

The proportion of patients who had received previous treatment for glaucoma varied among the treatment groups, with the bimatoprost group having the highest percentage (74.3%), followed by latanoprost (46%). It would have been helpful to know why the bimatoprost group had the greatest proportion of previously treated patients but, unfortunately, the study did not gather this information.

One strength of this study was that it enabled patient persistence with the study drugs to be quantified, an important factor to bear in mind when deciding between pharmacologic options, which may result in improved disease management.

Regarding variables related to persistence, it should be emphasized that, even though comorbidities did not appear to be directly related to persistence, patient age was found to be significantly related.

One of the study limitations is the absence of efficacy measurements (in terms of IOP reduction), in order to study whether this might be a factor influencing persistence. As previously mentioned, no reliable data on baseline IOP levels were available, from which effectiveness of the treatments could have been calculated.

In conclusion, at present, multiple monotherapy and combination therapy options are available for glaucoma and OHT management. Thus, the strategy selected to maximize the clinical benefit while minimizing associated health expenses will be critical.

Latanoprost has shown greater patient persistence than travoprost, bimatoprost, and timolol in routine clinical practice, resulting in better control of IOP levels, and lower associated costs. This attributes should avoid the occurrence or progression of complications, improve quality of care for glaucomatous patients, and result in a considerable resource saving for the national health system.
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###### 

Characteristics of study patients

                                                                             Latanoprost (n = 87)   Bimatoprost (n = 35)   Travoprost (n = 26)   Timolol (n = 43)   *P* value
  -------------------------------------------------------------------------- ---------------------- ---------------------- --------------------- ------------------ -----------
  Age (years), mean ± SD                                                     64.8 (12.8)            68.5 (14.05)           67.5 (16.8)           67.5 (14.4)        NS
  **Gender, n (%)**                                                                                                                                                 0.002
   Males                                                                     30 (34.5)              24 (68.6)              7 (26.9)              21 (48.8)          
   Females                                                                   57 (65.5)              11 (31.4)              19 (73.1)             22 (51.2)          
  Last IOP value (mmHg), mean ± SD                                           16.6 (2.7)             17.0 (2.9)             17 (2.5)              17.4 (3.4)         NS
  Glaucoma (years)[\*](#tfn1-opth-4-261){ref-type="table-fn"}, median ± SD   2.5 (4.1)              2.8 (2.9)              1.6 (1.5)             1.4 (3.5)          NS
  Previous glaucoma treatment, n (%)                                         40 (46)                26 (74.3)              8 (30.8)              11 (25.6)          0.00011
  **Associated comorbidities, n (%)**                                                                                                                               NS
   None                                                                      47 (54)                18 (51.4)              6 (23.1)              20 (46.5)          
   Cardiovascular (includes diabetes)                                        31 (35.6)              12 (34.3)              16 (61.5)             21 (48.8)          
   Ophthalmologic                                                            8 (9.2)                5 (14.3)               3 (11.5)              1 (2.3)            
   Neurologic                                                                1 (1.1)                0 (0)                  1 (3.8)               1 (2.3)            

**Notes:**

Time since glaucoma diagnosis (years).

Including diabetes mellitus.

**Abbreviation**: NS, not statistically significant.

###### 

Patient persistence with treatment

  N (%)                          Latanoprost (n = 87)   Bimatoprost (n = 35)   Travoprost (n = 26)   Timolol (n = 43)   *P*
  ------------------------------ ---------------------- ---------------------- --------------------- ------------------ ---------------
  No treatment discontinuation   71 (81.6)              8 (22.9)               17 (65.4)             26 (60.5)          *P* \< 0.0001
  Treatment discontinuation      16 (18.4)              27 (77.1)              9 (34.6)              17 (39.5)          

###### 

Degree of patient persistence with the study drugs

                n    Persistence (%)   Difference   *P* value
  ------------- ---- ----------------- ------------ -----------
  Latanoprost   87   18.6              58.7         0.0001
  Bimatoprost   35   22.9                           
  Latanoprost   87   81.6              16.2         0.058
  Travoprost    26   65.4                           
  Latanoprost   87   81.6              21.1         0.01
  Timolol       43   60.5                           
  Bimatoprost   35   22.9              −42.5        0.003
  Travoprost    26   65.4                           
  Bimatoprost   35   22.9              −37.6        0.001
  Timolol       43   60.5                           
  Travoprost    26   65.4              4.9          0.8
  Timolol       43   60.5                           

###### 

Reasons for withdrawal from treatment during the study

  Reason from treatment for withdrawal n (%)   Latanoprost (n = 87)   Bimatoprost (n = 35)   Travoprost (n = 26)   Timolol (n = 43)   *P* value
  -------------------------------------------- ---------------------- ---------------------- --------------------- ------------------ --------------
  Intolerance and/or adverse effects           2 (2.3)                10 (28.6)              6 (23.1)              4 (9.3)            *P* \< 0.001
  Lack of efficacy                             14 (16.1)              17 (48.6)              3 (11.5)              13 (30.2)          *P* \< 0.001
